Hepatitis C Virus (HCV) GenoSure® NS3/4A
Also known as: HCV Drug Resistance, NS3/4 Resistance Analysis, Q80K Polymorphism
Use
Assessment of drug susceptibility by nucleic acid sequencing of a patient's hepatitis C virus (HCV) to the NS3/4A protease inhibitors. Detects Q80K polymorphism. Assay should be used for patients with documented HCV genotype 1.
Special Instructions
It is critical to indicate the patient's specific HCV genotype (either 1a or 1b) when submitting the test request form. Ensure that specimens are collected, processed, and stored following the detailed procedures to avoid any delays or issues in testing accuracy.
Limitations
The procedure may not succeed if the viral load is below 2000 IU/mL. Additionally, this assay is limited to patients with an HCV genotype of 1a or 1b. Care must be taken to use the correct specimen collection methods, as specimens not meeting criteria will be subject to rejection.
Methodology
NGS (Targeted)
Biomarkers
LOINC Codes
- 32286-7
- 77202-0
Result Turnaround Time
10-14 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
2 mL
Minimum Volume
1 mL
Container
PPT™ or screw-capped polypropylene frozen transport tube.
Collection Instructions
Collect in one PPT™ tube, gel-barrier tube, or lavender-top (EDTA) tube. Do not use green-top (heparin) tubes. Centrifuge within six hours, transfer serum/plasma to polypropylene screw-capped tubes, and freeze. Ship frozen.
Storage Instructions
Freeze.
Causes for Rejection
PPT™ not centrifuged; insufficient volume; heparinized plasma; nonfrozen specimens; repeated freeze/thaw cycles; pop-top/snap-cap tubes.